• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Complementopathies.补体病
Blood Rev. 2017 Jul;31(4):213-223. doi: 10.1016/j.blre.2017.02.003. Epub 2017 Feb 6.
2
Complement in hemolytic anemia.溶血性贫血中的补体
Hematology Am Soc Hematol Educ Program. 2015;2015:385-91. doi: 10.1182/asheducation-2015.1.385.
3
Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.新型冠状病毒时代的补体介导溶血性贫血:病例系列及文献复习。
Front Immunol. 2021 Nov 25;12:791429. doi: 10.3389/fimmu.2021.791429. eCollection 2021.
4
A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway.补体替代途径及其与 HELLP 综合征关系的研究进展:是否应将 HELLP 综合征视为补体替代途径疾病。
J Matern Fetal Neonatal Med. 2022 Apr;35(7):1392-1400. doi: 10.1080/14767058.2020.1755650. Epub 2020 Apr 26.
5
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.依库珠单抗抗补体 C5 治疗阵发性睡眠性血红蛋白尿症和非典型溶血尿毒综合征。
Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20.
6
Eculizumab in pregnancy: a narrative overview.妊娠期间使用依库珠单抗:叙事性综述。
J Nephrol. 2019 Feb;32(1):17-25. doi: 10.1007/s40620-018-0517-z. Epub 2018 Aug 29.
7
Molecular pharmacology in complement-mediated hemolytic disorders.补体介导的溶血性疾病的分子药理学。
Eur J Haematol. 2023 Sep;111(3):326-336. doi: 10.1111/ejh.14026. Epub 2023 Jun 12.
8
Diseases of complement dysregulation-an overview.补体调控异常相关疾病概述。
Semin Immunopathol. 2018 Jan;40(1):49-64. doi: 10.1007/s00281-017-0663-8. Epub 2018 Jan 11.
9
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.小分子因子 D 抑制剂可选择性阻断阵发性夜间血红蛋白尿和非典型溶血尿毒症综合征中补体的替代途径。
Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.
10
Complement in hemolytic anemia.溶血性贫血中的补体
Blood. 2015 Nov 26;126(22):2459-65. doi: 10.1182/blood-2015-06-640995. Epub 2015 Nov 18.

引用本文的文献

1
Evolving understanding of Guillain-Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury.对吉兰-巴雷综合征病理生理学的认识不断发展以及经典补体途径在轴突损伤中的核心作用。
Front Neurol. 2025 May 14;16:1572949. doi: 10.3389/fneur.2025.1572949. eCollection 2025.
2
Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report.重度冷凝集素病患者自体干细胞移植的治疗方法:一例报告
Transfusion. 2025 Mar;65(3):637-642. doi: 10.1111/trf.18147. Epub 2025 Jan 28.
3
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients.可溶性尿激酶型纤溶酶原激活物受体 (suPAR)、生长分化因子 15 (GDF-15) 和可溶性 C5b-9 (sC5b-9) 水平与 CAR-T 细胞受者的内皮损伤指标显著相关。
Int J Mol Sci. 2024 Oct 14;25(20):11028. doi: 10.3390/ijms252011028.
4
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.冷球蛋白血症患者长期使用苏替利单抗后患者报告结局的持续改善:CADENZA研究开放标签扩展的结果
EClinicalMedicine. 2024 Jul 18;74:102732. doi: 10.1016/j.eclinm.2024.102732. eCollection 2024 Aug.
5
Mechanism of complement inhibition by a mosquito protein revealed through cryo-EM.通过冷冻电镜揭示了蚊子蛋白对补体的抑制机制。
Commun Biol. 2024 May 27;7(1):649. doi: 10.1038/s42003-024-06351-x.
6
The Importance of Early Suspicion for Cold Autoimmune Hemolytic Anemia.早期怀疑冷凝集素型自身免疫性溶血性贫血的重要性。
Cureus. 2023 Nov 21;15(11):e49160. doi: 10.7759/cureus.49160. eCollection 2023 Nov.
7
Kidney Involvement in Autoinflammatory Diseases.自身炎症性疾病中的肾脏受累
Kidney Dis (Basel). 2023 Feb 28;9(3):157-172. doi: 10.1159/000529917. eCollection 2023 May.
8
A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.一种新型双特异性补体和凝血抑制剂通过一种新机制阻断补体病模型中的激活。
Blood. 2023 Jun 22;141(25):3109-3121. doi: 10.1182/blood.2022019359.
9
Beyond IBD: the genetics of other early-onset diarrhoeal disorders.超越 IBD:其他早发性腹泻疾病的遗传学。
Hum Genet. 2023 May;142(5):655-667. doi: 10.1007/s00439-023-02524-6. Epub 2023 Feb 14.
10
Recent progress in ITP treatment.免疫性血小板减少症治疗的最新进展
Int J Hematol. 2023 Mar;117(3):316-330. doi: 10.1007/s12185-022-03527-1. Epub 2023 Jan 9.

本文引用的文献

1
Can eculizumab be discontinued in aHUS?: Case report and review of the literature.依库珠单抗能否在非典型溶血性尿毒症综合征(aHUS)中停用?:病例报告及文献综述
Medicine (Baltimore). 2016 Aug;95(31):e4330. doi: 10.1097/MD.0000000000004330.
2
Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak.典型溶血尿毒综合征:日托机构疫情中急性期补体激活的证据
J Clin Exp Nephrol. 2016;1(2). doi: 10.21767/2472-5056.100011. Epub 2016 May 6.
3
Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome.染色体重排——补体因子I相关非典型溶血尿毒综合征的罕见病因。
Immunobiology. 2016 Oct;221(10):1124-30. doi: 10.1016/j.imbio.2016.05.002. Epub 2016 May 10.
4
Examining coagulation-complement crosstalk: complement activation and thrombosis.研究凝血-补体相互作用:补体激活与血栓形成。
Thromb Res. 2016 May;141 Suppl 2:S50-4. doi: 10.1016/S0049-3848(16)30365-6.
5
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.依库珠单抗介导的补体末端途径抑制的结构基础。
J Immunol. 2016 Jul 1;197(1):337-44. doi: 10.4049/jimmunol.1600280. Epub 2016 May 18.
6
Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.HELLP综合征中补体激活的直接证据:与非典型溶血性尿毒症综合征的联系。
Exp Hematol. 2016 May;44(5):390-8. doi: 10.1016/j.exphem.2016.01.005. Epub 2016 Feb 26.
7
A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.补体激活调节因子簇中的新生缺失产生杂合补体因子H/补体因子H相关3基因,见于非典型溶血尿毒综合征。
J Am Soc Nephrol. 2016 Jun;27(6):1617-24. doi: 10.1681/ASN.2015010100. Epub 2015 Oct 21.
8
Complement System Part I - Molecular Mechanisms of Activation and Regulation.补体系统 第一部分——激活与调节的分子机制
Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015.
9
Complement System Part II: Role in Immunity.补体系统第二部分:在免疫中的作用。
Front Immunol. 2015 May 26;6:257. doi: 10.3389/fimmu.2015.00257. eCollection 2015.
10
Complement regulator CD46: genetic variants and disease associations.补体调节蛋白CD46:基因变异与疾病关联
Hum Genomics. 2015 Jun 10;9(1):7. doi: 10.1186/s40246-015-0029-z.

补体病

Complementopathies.

作者信息

Baines Andrea C, Brodsky Robert A

机构信息

Division of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

出版信息

Blood Rev. 2017 Jul;31(4):213-223. doi: 10.1016/j.blre.2017.02.003. Epub 2017 Feb 6.

DOI:10.1016/j.blre.2017.02.003
PMID:28215731
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5513767/
Abstract

The complement system is an essential part of the innate immune system that requires careful regulation to ensure responses are appropriately directed against harmful pathogens, while preventing collateral damage to normal host cells and tissues. While deficiency in some components of the complement pathway is associated with increased susceptibility to certain infections, it has also become clear that inappropriate activation of complement is an important contributor to human disease. A number of hematologic disorders are driven by complement, and these disorders may be termed "complementopathies". This includes paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), cold agglutinin disease (CAD) and other related disorders, which will be the focus of this review. A better understanding of the central role of the complement system in the pathophysiology of these disorders may allow for application of therapies directed at blocking the complement cascade.

摘要

补体系统是固有免疫系统的重要组成部分,需要精细调节以确保免疫反应能准确针对有害病原体,同时防止对正常宿主细胞和组织造成附带损害。虽然补体途径某些成分的缺陷与对某些感染的易感性增加有关,但补体的不适当激活显然也是人类疾病的一个重要促成因素。许多血液系统疾病是由补体驱动的,这些疾病可被称为“补体病”。这包括阵发性夜间血红蛋白尿(PNH)、非典型溶血性尿毒症综合征(aHUS)、冷凝集素病(CAD)及其他相关疾病,这些将是本综述的重点。更好地理解补体系统在这些疾病病理生理学中的核心作用,可能有助于应用针对阻断补体级联反应的疗法。